Search the Newsreel

Gossamer Bio: Q2 Earnings Snapshot

Gossamer Bio (GOSS) cuts debt but flags going concern and liquidity strain

Gossamer Bio, Inc. 2026: Revenue $9.24M, Net income $16.9M, EPS ($0.08) — 10-Q Summary

Gossamer Bio, Inc. reported its current quarter 2026 financial results, showing revenue of $9.24 million and a net income of $16.9 million, a significant improvement from a net loss in the prior year. The company also highlighted positive Phase 3 clinical trial results for …

Gossamer Bio Inc (GOSS) News, Articles, Events & Latest Updates

Gossamer Bio Inc (GOSS) recently reported its Q2 2026 financial results, showing a loss but exceeding revenue estimates. The company, a clinical-stage biopharmaceutical firm, is focusing on developing seralutinib for pulmonary arterial hypertension. Several legal firms are investigating the company, and its stock has …

GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS)

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm

Kuehn Law is investigating whether officers and directors of Gossamer Bio, Inc. (GOSS) breached their fiduciary duties due to alleged misrepresentations about its Phase 3 PROSERA study. The lawsuit claims the company failed to disclose issues with the study's design, leading to artificially inflated …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gossamer Bio, Inc. (NASDAQ: GOSS) securities. The investigation focuses on whether Gossamer and its officers engaged in corporate wrongdoing. The firm encourages investors who bought Gossamer shares before June 16, …

Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Gossamer Bio Inc (GOSS) has an earnings forecast score of 6.50, ranking 325 out of 387 in its industry, with an average price target of $9.00 based on 8 analysts. The market expects the company's revenue for the next quarter to be $5.19M and …

Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Gossamer Bio, Inc. (NASDAQ:GOSS) on behalf of investors who purchased securities prior to June 16, 2025, and still hold them. The investigation focuses on whether Gossamer's officers and/or directors engaged in corporate wrongdoing. The …

gossamer bio inc. Earnings dates

This article provides the upcoming earnings dates for Gossamer Bio Inc. (GOSS), including estimates for Q3 2024 and Q4 2025. It also lists recent news headlines related to Gossamer Bio, covering topics such as FDA filings, clinical trial results, and acquisitions.

BlackRock (GOSS) discloses 4.89M-share, 1% beneficial stake in Gossamer Bio

BlackRock, Inc. has filed an amended ownership report disclosing a beneficial stake of 4,890,593 shares, representing 1.0% of Gossamer Bio, Inc.'s common stock, as of June 30, 2026. BlackRock holds sole voting and sole dispositive power over these shares. This filing, a Schedule 13G/A, …

Gossamer Bio Inc (GOSS) Institutional Confidence

Gossamer Bio Inc (GOSS) has an institutional shareholding score of 7.00, placing it 80th out of 385 in its industry. The latest institutional shareholding proportion is 73.39%, representing a quarterly decrease of 6.63%. James Simons is identified as the largest institutional shareholder, holding 0.52% …

Opaleye group (NASDAQ: GOSS) reports 24.9M-share, 5.10% Gossamer Bio position

Opaleye Management Inc., along with Opaleye, L.P., and James Silverman, has disclosed a 5.10% beneficial ownership stake in Gossamer Bio, Inc. (GOSS), totaling 24,942,565 shares. This includes 24,141,629 shares held directly by Opaleye, L.P. and an additional 800,936 shares in a separately managed account. …

Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment

Gossamer Bio's stock showed significant pre-bell gains after the company announced its plans to file a New Drug Application (NDA) for its pulmonary arterial hypertension (PAH) treatment, seralutinib. This positive market response follows encouraging trial results for the drug. The company expects to submit …

Leerink upgrades Gossamer Bio stock rating on FDA feedback

Leerink upgraded Gossamer Bio Inc. (NASDAQ:GOSS) to Outperform from Market Perform, raising its price target to $1.00 following positive FDA feedback on the company's PROSERA trial. The FDA's assessment of the trial's statistical significance as a review issue rather than a filing issue reduced …

Gossamer Bio (GOSS) Projected to Release Quarterly Earnings on Tuesday

Leerink Partners Upgrades Gossamer Bio(GOSS.US) to Buy Rating, Cuts Target Price to $1

Leerink Partners has upgraded its rating for Gossamer Bio (GOSS.US) to "Buy." Despite the upgrade, the target price for the stock has been reduced to $1.

Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Gossamer Bio Inc (GOSS), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 6.30 and is trading within a range suitable …

12 Health Care Stocks Moving In Monday's After-Market Session

This article lists 12 healthcare stocks that experienced significant movement in Monday's after-market session, highlighting both gainers and losers. Notable gainers include Gossamer Bio, ProMIS Neurosciences, OPKO Health, OrthoPediatrics, Matinas BioPharma Hldgs, and Olema Pharmaceuticals. Conversely, Radiopharm Theranostics, Redhill Biopharma, HeartSciences, iBio, Cumberland Pharma, …

Gossamer Reacquires Global Seralutinib Rights From Chiesi, Receives $5 Million

Gossamer Bio has reacquired the global development and commercial rights for seralutinib from Chiesi, terminating their 2024 Collaboration and License Agreement. Chiesi will pay Gossamer $5 million for development costs, while Gossamer will pay success-based milestones and royalties to Chiesi. This move returns key …

Gossamer Bio shares jump after FDA update and seralutinib rights return

Gossamer Bio (NASDAQ:GOSS) shares surged 25% following a positive FDA regulatory update for its lead drug candidate, seralutinib, and the regaining of full global rights to the therapy. The company anticipates submitting a New Drug Application (NDA) for seralutinib in pulmonary arterial hypertension (PAH) …

Gossamer Bio stock surges 25% on FDA regulatory update

Gossamer Bio Inc. (NASDAQ:GOSS) shares surged 25% after the company announced a regulatory update from the FDA regarding its drug seralutinib for pulmonary arterial hypertension (PAH) and reacquired worldwide rights to the drug. The company plans to submit a New Drug Application (NDA) for …

Gossamer Bio shares surge after FDA filing update; cash concerns and dilution still loom

Gossamer Bio, Inc. Revenue Breakdown – SWB:4GB

This article from TradingView provides a high-level overview of Gossamer Bio, Inc.'s financial information on the Stuttgart Stock Exchange (SWB:4GB). It indicates that the primary financial segment information for revenue breakdown, including source and country, is not publicly available on this specific page. The …

GOSS|Gossamer Bio Inc|Price:0.136|Chg%:-0.006

Gossamer Bio Inc. (GOSS) is a late-stage biopharmaceutical company focusing on seralutinib for pulmonary arterial hypertension. The company exhibits stable fundamentals and high growth potential but is currently considered fairly valued within its industry. Despite weak recent stock market performance, its stock price is …

Form 13D/A Gossamer Bio For: 24 July By Investing.com

This article announces the filing of a Form 13D/A for Gossamer Bio on July 24. The filing is a standard regulatory disclosure related to significant ownership stakes in a company. The article itself is very brief, mainly serving as an announcement for this regulatory …

Gossamer Bio Inc (GOSS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Gossamer Bio Inc (GOSS), noting its current valuation score of 7.94 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio and mentions that relevant data for P/B, P/S, and P/CF ratios have not …

D. E. Shaw group reports 7.1% stake in Gossamer Bio (GOSS)

The D. E. Shaw group has updated its ownership disclosure for Gossamer Bio (GOSS), revealing affiliated investment entities collectively hold a 7.1% stake, totaling 34,609,565 common shares. This ownership is distributed among D. E. Shaw Valence Portfolios (6.7%), D. E. Shaw Cogence Portfolios (0.3%), …

Gossamer Bio stock edges higher as trial setbacks and restructuring reshape outlook

Gossamer Bio's stock reflects a mixed sentiment as the biotechnology company embarks on a restructuring phase following the discontinuation of its lead GB002 program. The company reported a significant reduction in net loss for 2023 due to decreased operating expenses and a refocused R&D …

Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B

Gossamer Bio (NASDAQ: GOSS) stockholders have approved a major increase in authorized common stock from 700 million to 4 billion shares. This decision, made at a special meeting on July 14, 2026, supports potential future share issuances related to new convertible notes, purchase warrants, …

Gossamer Bio (GOSS) Stock Forecast and Price Target 2026